Does Rallies track congressional trades in SABS?

Yes. Rallies tracks politician and congressional stock disclosures for SABS, including reported purchases, sales, dates, owners, and trade amounts when available.

Is SABS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for SABS. It does not provide personalized investment advice.

SABS (SAB Biotherapeutics, Inc. Common Stock) Stock Analysis - Politician Trades

SAB Biotherapeutics, Inc. Common Stock (SABS) is a publicly traded Healthcare sector company. As of May 21, 2026, SABS trades at $3.58 with a market cap of $272.21M and a P/E ratio of 16.77. SABS moved +3.66% today. Year to date, SABS is -1.60%; over the trailing twelve months it is +99.71%. Its 52-week range spans $1.00 to $6.60. Analyst consensus is strong buy with an average price target of $12.17. Rallies surfaces SABS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded SABS stock?

Rallies tracks politician and congressional stock disclosures for SABS, including purchases, sales, transaction dates, owners, and reported trade amounts when available.

SABS Key Metrics

Key financial metrics for SABS
Metric	Value
Price	$3.58
Market Cap	$272.21M
P/E Ratio	16.77
EPS	$0.22
Dividend Yield	0.00%
52-Week High	$6.60
52-Week Low	$1.00
Volume	1.58K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$13.27M
Gross Margin	0.00%

Latest SABS News

SAB Biotherapeutics Starts GMP Manufacturing, Expands Plasma Network 30% in Q1 — May 13, 2026
SAB Biotherapeutics Secures $95M, FDA Accepts C-Peptide Surrogate in SAFEGUARD Trial — May 12, 2026
SAB Biotherapeutics Raises $85M Offering to Advance SAB-142 Trials — Mar 19, 2026
SAB Biotherapeutics Unveils Phase IIb SAB-142 Trial With C-peptide Endpoint Set for 2027 — Mar 1, 2026

Recent SABS Insider Trades

Sullivan Eddie Joe bought 1.74K (~$1.53K) on Dec 7, 2023.
King Michael bought 5.00K (~$4.50K) on Nov 30, 2023.

SABS Analyst Consensus

7 analysts cover SABS: 0 strong buy, 7 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $12.17.

Common questions about SABS

Which politicians traded SABS stock?: Rallies tracks politician and congressional stock disclosures for SABS, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
Does Rallies track congressional trades in SABS?: Yes. Rallies tracks politician and congressional stock disclosures for SABS, including reported purchases, sales, dates, owners, and trade amounts when available.
Is SABS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for SABS. It does not provide personalized investment advice.